This is the authors' abstract. We don't add key points for this paper.
The synthesis of enlicitide decanoate (MK-0616), a first-in-class oral PCSK9 inhibitor, requires efficient Cbz deprotection of a proline–threonine dipeptide intermediate, presenting safety and economic challenges for traditional batch hydrogenation. Here, we report the development of a continuous trickle-bed flow reactor with customized components that addresses these manufacturing constraints through systematic process optimization. This paper reports the development of a laboratory-scale trickle-bed flow reactor with customized components on a commercially available system along with catalyst characterization and continuous temperature mapping. The optimized process achieved complete conversion with 3.8% catalyst loading (24% reduction versus batch processing) and maintained a robust performance over extended operations. This comprehensive development establishes a scalable, safer alternative to batch hydrogenation while reducing precious-metal usage, providing a template for pharmaceutical flow chemistry applications requiring heterogeneous catalysis.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Whittington et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: